Difference between revisions of "Epoetin alfa (Procrit)"
Jump to navigation
Jump to search
(updated content) |
m |
||
| Line 20: | Line 20: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category: | + | [[Category:Erythrocyte growth factors]] |
Revision as of 19:33, 17 May 2014
Also known as Epogen, epo, erythropoetin, or Procrit.
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Epoetin alfa (Procrit) patient instructions for use[5][6]
- Brief patient counseling information can be found on pages 25-26 of the Epoetin alfa (Procrit) package insert[1]
- Epoetin alfa (Procrit) patient drug information (Chemocare)[7]
- Epoetin alfa (Procrit) patient drug information (UpToDate)[8]
References
- ↑ 1.0 1.1 1.2 Epoetin alfa (Procrit) package insert
- ↑ Epoetin alfa (Procrit) package insert (locally hosted backup)
- ↑ Procrit manufacturer's website
- ↑ ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Epoetin alfa (Procrit) patient instructions for use
- ↑ Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)
- ↑ Epoetin alfa (Procrit) patient drug information (Chemocare)
- ↑ Epoetin alfa (Procrit) patient drug information (UpToDate)